X-Message-Number: 12497 Date: Sat, 2 Oct 1999 23:47:10 -0400 From: Mike Darwin <> Subject: Copy of: clamoring for anything better ---------- Forwarded Message ---------- From: Mike Darwin, 75120,575 TO: Tim Freeman, INTERNET: DATE: 10/1/99 3:03 AM RE: Copy of: clamoring for anything better Tim: From: Mike Darwin <> >As the behavior of the cryonis community clearly indicates, >they are not clamoring for anything better and don't really want to deal >with bad news of any kind. >If you want to say this, and you want to do anything about it, then >you should have details about the better things in your pocket, ready >to hand out when individuals clamor for them. Alcor is a charitable >organization and, to some extent, what they do is determined by what >the donors are willing to pay for. So it's important for the >potential donors to hear your better ideas, with price information >included. -- Tim Freeman http://www.infoscreen.com/resume.html Web-centered Java, Perl, and C++ programming in Silicon Valley or offsite Each cryonics organiztion has its own agenda driven by its own micro-environment of tempraments and world-views. There is nothing unusual in this. This happens in every business or organization. Normally these agendas are corrected by brutal market forces if they are not conducive to the institution's survival. Most institutions have CUSTOMERS who provide this feedback. (You can call them clients, members or whatever, but the principle is the same.) In the normal course of affairs the feedback loop is short, and the bandwidth of consumer information expands or contracts with the degree of concern or confidence about the quality of the goods or services being received (If you were a Ford Mustang owner (or whatever model it was) you probably didn't pay much attention to the mechanics of gasoline tank placement until you started reading about people getting incinerated as a result of minor rear-end collisions.) Even then, it can be tough call to sort out what's the truth and then decide what to do: if you play the stock market at all you surely understand this :-). Finally, the size and sophistication of the market generally provide built-in corrective or feedback generating mechanisms. Cryonics lacks all these things. Merkle argues cryonics is an experiment with "controls" and "experimentals" and asks rhetorically "which group do you want to be in?" But this is wrong, very wrong. For as any competent scientist knows the FIRST thing you do when set out to do science is to come up with an experimental *design* which lays out the core parameters of how you will proceed, how you will generate and validate your feedback, and so on. This is called a *protocol* and I am required by Federal law to have one (usually about 100 pages long) including statistics, contingency plans, and criteria for modification before I can experiment on any *animal.* In theory, IF cryonics were really being practiced as experimental science then that's what you would do, at a minimum. You'd not be able to specify in advance every procedure to be used for patients as the technology evolved (just you can't in a real-time experiment), but you would be able to set standards and guidelines for evaluating changes to the initial (starting) technology and you would generate a system of internal quality controls based on your fundamental hypothesis. In cryonics this fundamental hypothesis and simple experimental design might go something like this: "Human mentation and identity are structurally/physically based. Any preservation technology which allows for inference of the operational (healthy alive) state of the patient should, in theory, allow for repair and recovery. Procedures should be optimized to preserve structure and function (which is a marker for currently unresolveable structure). Quality control should be present in a number of forms and an integral and evolving part of the program to provide feedback on how well current treatments meet their *predefined* criteria, as well as how any modifications act to improve or degrade structure and function. Considerations such as cost versus benefit of any given intervention must also be made, and these will be especially difficult within limited cost constraints. Mechanisms for resolving these issues should be put in place as early as possible in the experimental program." The above is VERY weak, but it provides some kind of floor for quality. EM's should be done on every patient, and data collected, archived, and made available to any potential experimental subject (customer) or others who desire to evaluate the state of the art. I could think of many very simple things that would tell a lot about how well or poorly a cryonics society is performing: What % of your patients experience what interval of ischemia before cardiopulmonary support is started? What is you mean time to blood washout, CPA perfusion, cooling to storage temp? And on and on. As it is, this kind of approach was abandoned. Now, it is impossible for the leaders of the organizations themselves to have any frame of reference but their own biases and concerns. There is no PROTOCOL, no BIBLE, nothing to guide them. And they are under intense pressure to keep costs low and services affordable to as many people as possible because "lives are at stake." In medicine, quality clinical trials are RUTHLESS, they have inclusion and exclusion criteria (in some places money is one of them!) and they are adhered to. Otherwise you just get junk for data. The leaders of ALL cryonics societies have been offered cost projections, detailed disclosure of the technology, and every other tool imagineable to allow them to make a decision. Alcor's response was that their first priority was to get people trained-up and facilities geared-up to the point where they could do cryopreservations at the level they were being done when Jerry Leaf and I were in tactical command. To me, this is like saying we're going to prepare for World War III by first learning how to use World II tactics. As it is, Saul has invested $50,000 in BioTransport. He is pushing very hard to convince the BioTransport people to train properly and to rapidly implement better cryopreservation protocols. I hope he succeeds. But I have grave doubts. To buy into to cryonics in the first place you have to believe (for most people) on some gut level that it will work for you. You count on progress, but you don't think much about where it will come from. You imagine the best scenario for yourself. Mosly you're just glad to have "dealt with the death problem," however inadequately, and just want to be a customer, trust your cryonics organization to do the VERY BEST for you, and get on with your life. Perfectly reasonable. Except it doesn't work. Life at the top of a cryonics organization is bitterly hard and stressful. Like Alice, you are often running as fast as you can just to stay in the same place. It takes some extraordinary cohones to go after yet a HIGHER level of technology AND risk losing some of your badly needed (and very tiny) customer base. That's how I see it with ACS and Alcor. Good intentions, but basically decisions are made for "the average member." Socialism. In the absence of PREDETERMINED standards there will be no way for anyone to evaluate what is the best course of action to take. Thus, they will take the easiest course. It's just that simple. I've gone on for far too long. Suffice it to say short of FORCING IT DOWN THEIR THROATS everybody in a position of responsibility and the capability to offer it (this excludes CryoCare since they have no service provider at the moment) has been given the oppportunity for access to this technology. However, they must be willing to implement it properly and responsibly. Maybe that, in the final analysis, is the one cost that is simply unthinkable. Mike Darwin Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=12497